7 September 2022 - Novel mechanism of action of Pluvicto binds to target PSMA positive cancer cells, delivering radiation treatment directly to those cells and nearby cells.

Advanced Accelerator Applications Canada is pleased to announce that Health Canada has approved Pluvicto (lutetium (177 Lu) vipivotide tetraxetan injection) for the treatment of adult patients with prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer who have received at least one androgen receptor pathway inhibitor and taxane-based chemotherapy.

Read Advanced Accelerator Applications press release